相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification
Karine Breckpot et al.
Endocrine Metabolic & Immune Disorders-Drug Targets (2012)
Induction of Immune Tolerance in Asthmatic Mice by Vaccination with DNA Encoding an Allergen-Cytotoxic T Lymphocyte-Associated Antigen 4 Combination
Fang Zhang et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
Michael A. Curran et al.
PLOS ONE (2011)
Vaccines and Immunotherapeutics for the Treatment of Malignant Disease
Joel F. Aldrich et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
Costimulation as a Platform for the Development of Vaccines: A Peptide-Based Vaccine Containing a Novel Form of 4-1BB Ligand Eradicates Established Tumors
Rajesh K. Sharma et al.
CANCER RESEARCH (2009)
4-1BBL costimulation retrieves CD28 expression in activated T cells
Mojtaba Habib-Agahi et al.
CELLULAR IMMUNOLOGY (2009)
Immune regulation by 4-1BB and 4-1BBL: complexities and challenges
Chao Wang et al.
IMMUNOLOGICAL REVIEWS (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
4-1BB (CD137) Ligand Enhanced Anti-Tumor Immune Response against Mouse Forestomach Carcinoma In Vivo
Qiaoxia Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2008)
The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer
David H. Lynch
IMMUNOLOGICAL REVIEWS (2008)
Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L
Xiaocai Yan et al.
JOURNAL OF IMMUNOLOGY (2008)
Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells
Mojtaba Habib-Agahi et al.
INTERNATIONAL IMMUNOLOGY (2007)
Cytotoxic T-Lymphocyte - Associated antigen-4
F. Stephen Hodi
CLINICAL CANCER RESEARCH (2007)
Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo
Han Xiao et al.
CLINICAL CANCER RESEARCH (2007)
B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro
Zhao-Yang Lu et al.
EXPERIMENTAL HEMATOLOGY (2007)
Immunology and immunotherapy approaches for prostate cancer
E. Elkord
PROSTATE CANCER AND PROSTATIC DISEASES (2007)
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity
Ergun Kocak et al.
CANCER RESEARCH (2006)
4-IBB ligand enhances tumor-specific immunity of poxvirus vaccines
Chie Kudo-Saito et al.
VACCINE (2006)
The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling
Ö Met et al.
CANCER LETTERS (2006)
Ligation of CD 137 receptor prevents and reverses established anergy of CD8(+) cytolytic T lymphocytes in vivo
RA Wilcox et al.
BLOOD (2004)
Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity?
M Croft
NATURE REVIEWS IMMUNOLOGY (2003)
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1
HW Lee et al.
JOURNAL OF IMMUNOLOGY (2002)
Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity
RA Wilcox et al.
JOURNAL OF IMMUNOLOGY (2002)
4-1BB co-stimulation enhances human CD8+ T cell priming by augmenting the proliferation and survival of effector CD8+ T cells
D Laderach et al.
INTERNATIONAL IMMUNOLOGY (2002)
4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy
JL Cannons et al.
JOURNAL OF IMMUNOLOGY (2001)
4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors
BA Guinn et al.
CELLULAR IMMUNOLOGY (2001)
分享论文
